Company: TELO
Filing Date: 2025-11-28
Form Type: PRER14A
Source: 0001493152-25-025406
Chunk: 107

Company: Telomir Pharmaceuticals, Inc.
Filing Date: 2025-11-28
Form: PRER14A
Chunk 107
---
:------------------------------------------|----------:|
| Erez Aminov, CEO                |     |         | 8/27/2024 |     |                                                                 | - |     |        | - |     |         | - |     |                                                 | - |     |        | - |     |         | - |     |                                                    | - |     |                                                          | 1,960,170 | -2 |     | $                                | 5.02 | -4 |     | $                            | 5.26 |     | $                                         | 7,513,332 |
| Michelle Yanez, CFO             |     |         | 8/27/2024 |     |                                                                 | - |     |        |   |     |         | - |     |                                                 | - |     |        | - |     |         | - |     |                                                    | - |     |                                                          |   200,000 | -3 |     | $                                | 5.02 | -4 |     | $                            | 5.26 |     | $                                         |   782,000 |
| Christopher Chapman, former CEO |     |         | -         |     |                                                                 | - |     |        | - |     |         | - |     |                                                 | - |     |        | - |     |         | - |     |                                                    | - |     |                                                          |         - |    |     |                                  |    - |    |     |                              |    - |     |                                           |         - |
| Nathen Fuentes, former CFO      |     |         | -         |     |                                                                 | - |     |        | - |     |         | - |     |                                                 | - |     |        | - |     |         | - |     |                                                    | - |     |                                                          |         - |    |     |                                  |    - |    |     |                              |    - |     |                                           |         - |

(1) The “Grant Date” represents the date on which the Compensation Committee of the Board took action to grant the applicable award

(2) The stock awards disclosed in this item consist of options, as issued under our 2023 Omnibus Incentive Plan, which vest 50% at grant date, and 50% six months from grant date.

(3)The stock awards disclosed in this item consist of options, as issued under our 2023 Omnibus Incentive Plan, which